Trametinib (DMSO solvate)
≥99%
- Product Code: 103000
CAS:
1187431-43-1
| Molecular Weight: | 693.53 g./mol | Molecular Formula: | C₂₈H₂₉FIN₅O₅S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Trametinib (DMSO solvate) is primarily used in cancer research and treatment, specifically targeting melanoma and other cancers with mutations in the MAPK pathway. It functions as a MEK inhibitor, blocking the activity of proteins involved in cancer cell growth and proliferation. This compound is often utilized in preclinical studies to evaluate its efficacy in inhibiting tumor progression and enhancing the effectiveness of combination therapies. In clinical settings, it is administered to patients with BRAF V600 mutation-positive cancers, often in combination with other targeted therapies, to improve treatment outcomes. Additionally, Trametinib (DMSO solvate) is employed in laboratory experiments to study cellular signaling pathways and develop novel therapeutic strategies for various malignancies.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Powder |
| Purity (%) | 98.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | $411.35 |
+
-
|
| 0.050 | 10-20 days | $821.70 |
+
-
|
| 0.250 | 10-20 days | $2,762.43 |
+
-
|
Trametinib (DMSO solvate)
Trametinib (DMSO solvate) is primarily used in cancer research and treatment, specifically targeting melanoma and other cancers with mutations in the MAPK pathway. It functions as a MEK inhibitor, blocking the activity of proteins involved in cancer cell growth and proliferation. This compound is often utilized in preclinical studies to evaluate its efficacy in inhibiting tumor progression and enhancing the effectiveness of combination therapies. In clinical settings, it is administered to patients with BRAF V600 mutation-positive cancers, often in combination with other targeted therapies, to improve treatment outcomes. Additionally, Trametinib (DMSO solvate) is employed in laboratory experiments to study cellular signaling pathways and develop novel therapeutic strategies for various malignancies.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :